Skip to main
PHGE
PHGE logo

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX Inc. is advancing its pipeline of phage-based therapies, with encouraging results from its BX211 Phase 2 trial for diabetic foot osteomyelitis indicating positive trends in clinical parameters, such as reduced infection and improved resolution as evidenced by imaging studies. The Company also received favorable feedback from the FDA regarding its BX011 multi-phage cocktail, which is set to enter a Phase 2a study, targeting multiple efficacy endpoints that could enhance lung function and quality of life in cystic fibrosis patients. Furthermore, the potential for increased market penetration and the addition of indications in various stages of development, along with broader accessibility beyond the U.S., positions BiomX for significant upside in valuation and commercial success.

Bears say

BiomX Inc. faces a negative outlook primarily due to investor sentiment shifting unfavorably following recent clinical trial results, notably as key endpoints achieved statistical significance but others narrowly missed the conventional threshold. Additionally, the company may encounter significant challenges, including the potential for failed or inconclusive clinical trials, difficulty in securing adequate funding for drug development, and the risk of dilutive capital raises. The culmination of these factors, alongside concerns regarding the commercial viability of its products, raises substantial uncertainties about the future performance of BiomX's stock.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.